Potential drug-drug interactions in hospitalized patients with COVID-19.

IF 0.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Acta poloniae pharmaceutica Pub Date : 2023-06-29 DOI:10.32383/appdr/162213
Danuta Szkutnik-Fiedler, Filip Kwiatkowski, Monika Chomej, D. Kołodziej, M. Michalak, E. Grześkowiak, E. Szałek
{"title":"Potential drug-drug interactions in hospitalized patients with COVID-19.","authors":"Danuta Szkutnik-Fiedler, Filip Kwiatkowski, Monika Chomej, D. Kołodziej, M. Michalak, E. Grześkowiak, E. Szałek","doi":"10.32383/appdr/162213","DOIUrl":null,"url":null,"abstract":"Most hospitalized patients with COVID-19 require complex pharmacotherapy due to underlying diseases, and polypharmacy may significantly increase the risk of drug-drug interactions (DDIs) and, in consequence, trigger adverse effects. The aim of this study was to assess the risk of potential DDIs during hospitalization in COVID-19 patients. A retrospective analysis of pharmacotherapy in 75 patients (age, Mean±SD, 63.6±14.9) with a proven diagnosis of SARS-CoV-2 infection was conducted. The analysis included drugs administered to treat comorbidities and the COVID-19 treatment. 524 moderate and 112 major interaction cases were revealed in the analyzed COVID-19 patients, and 84% of the patients were exposed to at least one major DDI. Drugs that caused the most frequently observed DDIs include macrolides, low molecular weight heparins, glucocorticosteroids, quinolones, and antihypertensive drugs. Most COVID-19 patients have comorbidities requiring polypharmacy, which increases the risk of DDIs. Therefore, additional monitoring should be considered due to potential adverse effects, drug conversion, and deprescription.","PeriodicalId":7147,"journal":{"name":"Acta poloniae pharmaceutica","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta poloniae pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32383/appdr/162213","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Most hospitalized patients with COVID-19 require complex pharmacotherapy due to underlying diseases, and polypharmacy may significantly increase the risk of drug-drug interactions (DDIs) and, in consequence, trigger adverse effects. The aim of this study was to assess the risk of potential DDIs during hospitalization in COVID-19 patients. A retrospective analysis of pharmacotherapy in 75 patients (age, Mean±SD, 63.6±14.9) with a proven diagnosis of SARS-CoV-2 infection was conducted. The analysis included drugs administered to treat comorbidities and the COVID-19 treatment. 524 moderate and 112 major interaction cases were revealed in the analyzed COVID-19 patients, and 84% of the patients were exposed to at least one major DDI. Drugs that caused the most frequently observed DDIs include macrolides, low molecular weight heparins, glucocorticosteroids, quinolones, and antihypertensive drugs. Most COVID-19 patients have comorbidities requiring polypharmacy, which increases the risk of DDIs. Therefore, additional monitoring should be considered due to potential adverse effects, drug conversion, and deprescription.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19住院患者的潜在药物相互作用
大多数COVID-19住院患者由于基础疾病需要复杂的药物治疗,多种药物治疗可能显著增加药物相互作用(ddi)的风险,从而引发不良反应。本研究的目的是评估COVID-19患者住院期间潜在ddi的风险。回顾性分析75例确诊为SARS-CoV-2感染的患者(年龄,Mean±SD, 63.6±14.9)的药物治疗情况。该分析包括用于治疗合并症和COVID-19治疗的药物。分析的COVID-19患者中发现中度交互作用病例524例,重度交互作用病例112例,84%的患者至少暴露于一种重度DDI。引起ddi最常见的药物包括大环内酯类药物、低分子肝素、糖皮质激素、喹诺酮类药物和降压药。大多数COVID-19患者有合并症,需要多重用药,这增加了ddi的风险。因此,由于潜在的不良反应、药物转化和取消处方,应考虑额外的监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
74
审稿时长
6-12 weeks
期刊介绍: The international journal of the Polish Pharmaceutical Society is published in 6 issues a year. The journal offers Open Access publication of original research papers, short communications and reviews written in English, in all areas of pharmaceutical sciences. The following areas of pharmaceutical sciences are covered: Analysis, Biopharmacy, Drug Biochemistry, Drug Synthesis, Natural Drugs, Pharmaceutical Technology, Pharmacology and General. A bimonthly appearing in English since 1994, which continues “Acta Poloniae Pharmaceutica”, whose first issue appeared in December 1937. The war halted the activity of the journal’s creators. Issuance of “Acta Poloniae Pharmaceutica” was resumed in 1947. From 1947 the journal appeared irregularly, initially as a quarterly, then a bimonthly. In the years 1963 – 1973 alongside the Polish version appeared the English edition of the journal. Starting from 1974 only works in English are published in the journal. Since 1995 the journal has been appearing very regularly in two-month intervals (six books a year). The journal publishes original works from all fields of pharmacy, summaries of postdoctoral dissertations and laboratory notes.
期刊最新文献
Sore throat: diagnosis and treatment world standards and approaches to pharmaceutical care in Ukraine Insulin resistance and iatrogenic hyperinsulinemia in type 1 diabetes - norm or complication? Role of metformin in type 1 diabetes mellitus Evaluation of Diacerein Efficacy on Colitis as Anti-inflammatory and Anti-oxidant and its Role in Enhancing of Colon Barrier in Mice Pharmacokinetic interaction of saxagliptin with andrographolide and their hypoglycemic effect in type 2 diabetes rats Panax ginseng C.A. Mey. as a potential raw material in the treatment of negative effects of alcohol consumption
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1